Market Movers

Elevance Health, Inc.’s Stock Price Plummets to $444.35, Marking a Sharp 10.59% Drop

By October 18, 2024 No Comments

Elevance Health, Inc. (ELV)

444.35 USD -52.61 (-10.59%) Volume: 8.28M

Explore Elevance Health, Inc.’s stock price performance, currently standing at 444.35 USD, witnessing a drop of 10.59% this trading session with a trading volume of 8.28M. The stock has seen a year-to-date decrease of 5.77%, making ELV’s financial health a hot topic for investors.


Latest developments on Elevance Health, Inc.

Elevance Health, Inc. faced a challenging quarter as its profit took a hit from a fall in Medicaid memberships, leading to a plunge in stock prices. The company reported strong Q3 2024 results but struggled with higher medical costs and issues with Medicaid redeterminations. Earnings fell short of expectations, causing the stock to tumble 12% and touch a 52-week low. Despite this setback, Elevance Health remains committed to overcoming industry headwinds and maintaining its stock price target. The company’s dividend declaration for the fourth quarter of 2024 shows resilience in the face of adversity.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

πŸ’‘ Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • βœ“ Unlimited Research Summaries
  • βœ“ Personalised Alerts
  • βœ“ Custom Watchlists
  • βœ“ Company Analytics and News
  • βœ“ Events & Webinars